<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01903252</url>
  </required_header>
  <id_info>
    <org_study_id>TP0503</org_study_id>
    <nct_id>NCT01903252</nct_id>
  </id_info>
  <brief_title>TP05 for the Treatment of Mild to Moderate Active Ulcerative Colitis (UC)</brief_title>
  <acronym>Precision-UC</acronym>
  <official_title>A Randomised, Active-Controlled, Double-Blind and Open Label Extensions Study to Evaluate the Efficacy, Long-Term Safety and Tolerability of TP05 3.2g/Day for the Treatment of Active Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tillotts Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tillotts Pharma AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study was to compare the medication TP05 to the medication
      Asacol™ for the treatment of ulcerative colitis (UC) and to assess the safety and
      tolerability of TP05. This study investigated whether TP05 is as good as (non-inferior to)
      Asacol™(1).

      (1)The trademark Asacol™ is registered in over 55 countries as Asacol™ and as Octasa™,
      Fivasa™, Lixacol™, Asacolon™ in the United Kingdom, France, Spain and Ireland, respectively.
      The rights to Asacol, including the rights to the trademark, are owned by Tillotts Pharma AG
      in various countries except for the following: Switzerland, USA, United Kingdom, Canada,
      Italy, Belgium, the Netherlands and Luxembourg.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3, randomised, double-blind, active-controlled, multi-centre, non-inferiority
      trial evaluating the safety and efficacy of 3.2 g of TP05/day compared to 3.2 g/day of
      Asacol™ with an open label extension to assess the long-term safety and tolerability of TP05
      administered over a 26 week period. A total of 817 subjects with mildly to moderately active
      UC were evaluated. Eligible subjects were randomly assigned in a 1:1 ratio to receive 3.2
      g/day of TP05 (administered once daily(OD)) or 3.2 g/day of Asacol™. The primary efficacy
      outcome was assessed at Week 8. All subjects who respond to TP05/Asacol™ (response or
      remission) continued receiving blinded study treatment for up to 12 weeks. After that,
      subjects could enroll in an Open Label Extension (OLE) for 26 weeks duration to receive TP05.
      Subjects failing to respond to study drug at the Week 8 visit could enroll in the OLE at week
      8 and received 4.8 g/day of TP05.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2013</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Period 1: Clinical and Endoscopic Remission</measure>
    <time_frame>Week 8</time_frame>
    <description>Mayo Score of &lt;= 2 points with no individual sub-score &gt; 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Period 2: Clinical Response, Open-Label Extended Induction</measure>
    <time_frame>Week 16</time_frame>
    <description>A decrease in the PMCS of ≥ 2 points and ≥ 30% from baseline, with a decrease in the rectal bleeding sub-score of ≥ 1 point or absolute rectal bleeding sub-score of 1 or 0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Period 3: Clinical Remission</measure>
    <time_frame>Week 38</time_frame>
    <description>Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Period 1: Endoscopic Remission</measure>
    <time_frame>Week 8</time_frame>
    <description>Endoscopic remission was defined as a Mayo endoscopy subscore of 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 1: Endoscopic Response</measure>
    <time_frame>Week 8</time_frame>
    <description>Endoscopic response was define as a reduction in the Mayo endoscopic sub score of at least one.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 1: Clinical Remission</measure>
    <time_frame>Week 8</time_frame>
    <description>Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 1: Rectal Bleeding Sub-score of 0</measure>
    <time_frame>Week 8</time_frame>
    <description>Rectal bleeding sub-score of 0 was defined as a sub score on the rectal bleeding component of the Mayo score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 1: Clinical and Endoscopic Response</measure>
    <time_frame>Week 8</time_frame>
    <description>Clinical and Endoscopic Response was defined as a decrease in the Mayo score of ≥3 points from baseline and a reduction of ≥ 30% from baseline with either an accompanying decrease in the rectal bleeding sub-score of at least 1 point or an absolute rectal bleeding sub-score of 0 or 1 at the Week 8 visit. If a subject withdrew from the study prior to Week 8 or their response status was not evaluable due to incomplete and/or invalid data, the subject was considered a non-responder.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 1: Clinical Remission</measure>
    <time_frame>Week 12</time_frame>
    <description>Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 1: Clinical Response</measure>
    <time_frame>Week 12</time_frame>
    <description>A decrease in the PMCS of ≥ 2 points and ≥ 30% from baseline, with a decrease in the rectal bleeding sub-score of ≥ 1 point or absolute rectal bleeding sub-score of 1 or 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 1: Rectal Bleeding Score of 0</measure>
    <time_frame>Week 12</time_frame>
    <description>Rectal bleeding sub-score of 0 was defined as a sub score on the rectal bleeding component of the Mayo score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 1: Clinical Remission at Both Week 8 and 12</measure>
    <time_frame>Week 8 and week 12</time_frame>
    <description>Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 1: Clinical Response at Both Week 8 and Week 12</measure>
    <time_frame>Week 8 and Week 12</time_frame>
    <description>A decrease in the Partial Mayo Score of ≥ 2 points and ≥ 30% from baseline, with a decrease in the rectal bleeding sub-score of ≥ 1 point or absolute rectal bleeding sub-score of 1 or 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 1: Change in Mayo Score From Baseline</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>Between-Group Difference of Mayo Score, Change from Baseline The changes from baseline to week 8 values in Mayo scores are compared between the two treatment groups.
The Mayo scoring system is a well-established tool for assessing UC disease activity. The Mayo score is the sum of 4 component sub-scores, each scored on a scale ranging from 0 representing no pathology to 3 for severe disease. The 4 component sub-scores consist of, 1) stool frequency, 2) rectal bleeding, 3) flexible sigmoidoscopy scores, and 4) physician's global assessment. A Mayo score of 0 indicates no pathology and a score of 12, severe disease. Change from Baseline is calculated Baseline-score minus week 8-score. A larger change in Mayo score from baseline when patients experienced acute disease, indicates improvement and treatment success.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 1: Change in Partial Mayo Score From Baseline</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>Between-Group Difference of Partial Mayo Score, Change from Baseline to Week 8 The Partial Mayo Score is the sum of the component sub-scores, 1) stool frequency, 2) rectal bleeding and 3) physician's global assessment. A partial Mayo Score of 0 indicates no disease and a maximum score of 9 indicates severe symptoms. Change from Baseline is calculated Baseline-score minus week 8-score. A larger change in Partial Mayo Score from Baseline where patients experienced acute disease, indicates improvement and treatment success.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 1: Change in Stool Frequency Score</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>Between-Group Difference of Stool Frequency Score, Change from Baseline The changes from baseline to week 8 values in stool frequency will be compared between the two treatment groups. Values for stool frequency range between 0 and 3. A value of 0 indicates normal stool frequency, a value of 3 indicates 5 or more stools than normal. Change from Baseline is calculated Baseline-score minus week 8-score. A large difference between week 8 values and baselines indicates treatment success.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 1: Change in Rectal Bleeding Score From Baseline</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>Between-Group Difference of Rectal Bleeding Score, Change from Baseline The changes from baseline to week 8 values in rectal bleeding scores will be compared between the two treatment groups. A value of 0 indicates no rectal bleeding, a value of 3 indicates only blood is passing. Change from Baseline is calculated Baseline-score minus week 8-score. A large difference at week 8 compared to baseline is indicative of treatment success.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 1: Change in Physician Global Assessment Score From Baseline</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>Between-Group Difference of Physician Global Assessment Score, Change from Baseline.
The changes from baseline to week 8 values in the Physician Global Assessment score will be compared between the two treatment groups. A value of 0 means no pathology and a value of 3 means severe disease. Change from Baseline is calculated Baseline-score minus week 8-score. A large difference between baseline to week 8 indicates treatment success.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 1: Change in Endoscopic Score From Baseline</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>Between-Group Difference of Endoscopic Score, Change from Baseline. The changes from baseline to week 8 values in sigmoidoscopic (mucosal) appearance scores will be compared between the two treatment groups. A value of 0 in the endoscopic score means normal or inactive disease and a value of 3 means severe disease. Change from Baseline is calculated Baseline-score minus week 8-score. A large difference between baseline to week 8 indicates treatment success.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 2: Clinical Remission</measure>
    <time_frame>Week 16</time_frame>
    <description>Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 2: Rectal Bleeding Sub-score of 0</measure>
    <time_frame>Week 16</time_frame>
    <description>Percentage of patients achieving the endpoint rectal bleeding sub-score of 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 2: Stool Frequency 0</measure>
    <time_frame>Week 16</time_frame>
    <description>Percentage of patients achieving the endpoint stool frequency sub-score of 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 2: Urgency</measure>
    <time_frame>Week 16</time_frame>
    <description>Percentage of patients achieving an Urgency Score of 0. A score of 0 indicates no urgency reported in any of the three days prior to the visit at week 16. A score of 1 indicates urgency reported in any of the three days prior to the visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 2: UC-Related Complications</measure>
    <time_frame>Week 16</time_frame>
    <description>Percentage of Patients Experiencing Complications related to UC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 3: Clinical Response</measure>
    <time_frame>Week 38</time_frame>
    <description>A decrease in the PMCS of ≥ 2 points and ≥ 30% from baseline, with a decrease in the rectal bleeding sub-score of ≥ 1 point or absolute rectal bleeding sub-score of 1 or 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 3: Clinical and Endoscopic Remission</measure>
    <time_frame>Week 38</time_frame>
    <description>Mayo Score of &lt;= 2 points with no individual sub-score &gt; 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 3: Clinical and Endoscopic Response</measure>
    <time_frame>Week 38</time_frame>
    <description>Both has to be achieved, Clinical and Endoscopic Response which is defined by a decrease from baseline in the Mayo score of ≥ 3 points and &gt; 30% of the baseline score, with an accompanying decrease in the rectal bleeding sub-score of ≥ 1 point or an absolute rectal bleeding sub-score of 0 or 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 3: Endoscopic Remission</measure>
    <time_frame>Week 38</time_frame>
    <description>Percentage of each dose group achieving an endoscopy sub score of 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 3: Endoscopic Response</measure>
    <time_frame>Week 38</time_frame>
    <description>Endoscopic response was define as a reduction in the Mayo endoscopic sub score of at least one.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 3: Rectal Bleeding Sub Score of 0</measure>
    <time_frame>Week 38</time_frame>
    <description>Percentage of each dose group achieving the endpoint rectal bleeding subscore 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 3: Stool Frequency Sub-score 0</measure>
    <time_frame>Week 38</time_frame>
    <description>Patients achieving a Stool Frequency sub-score of 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 3: No Urgency</measure>
    <time_frame>Week 38</time_frame>
    <description>No urgency is a score of 0 and indicates that patients did not report urgency during any of the three days prior to the visit at week 38. A score of 1 indicates that urgency was reported during any of these three days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period 3: UC-Related Complications</measure>
    <time_frame>Week 38</time_frame>
    <description>Percentage of Patients with Complications related to UC</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">817</enrollment>
  <condition>Acute Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>TP05 (Mesalazine) 1600mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>week 1 - week 12 (blinded), week 13 - week 38 (OpenLabel)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asacol 400 mg (Tillotts Pharma)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>week 1 - week 12 (blinded), switch to TP05 for weeks 13-38 (open label)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TP05</intervention_name>
    <description>3.2g/day once daily for 12 weeks (blinded), 1.6g/d - 4.8g/d up to week 38 (open label)</description>
    <arm_group_label>TP05 (Mesalazine) 1600mg</arm_group_label>
    <other_name>Mesalazine 1600 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asacol 400 mg</intervention_name>
    <description>3.2g/d twice daily for 12 weeks (blinded), switch to 1.6g/ - 4.8g/d TP05 up to week 38 (open label)</description>
    <arm_group_label>Asacol 400 mg (Tillotts Pharma)</arm_group_label>
    <other_name>Mesalazine (Tillotts Pharma AG)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Induction phase - Main criteria for inclusion include:

          1. Male or non-pregnant, non-lactating females, 18 years of age or older. Females of
             child bearing potential must have a negative serum pregnancy test prior to
             randomisation, and must use a hormonal (oral, implantable or injectable) or barrier
             method of birth control throughout the study. Females unable to bear children must
             have documentation of such in the source records (i.e., tubal ligation, hysterectomy,
             or post-menopausal [defined as a minimum of one year since the last menstrual
             period]).

          2. Documented diagnosis of UC with disease extending at least 15 cm from the anal verge.

          3. Active UC defined by:

               -  a. Mayo score of ≥ 5

               -  b. Sigmoidoscopy component score ≥ 2 confirmed by central review and

               -  c. Rectal bleeding component score ≥ 1

          4. Ability of the subject to participate fully in all aspects of this clinical trial.

          5. Written informed consent must be obtained and documented.

        Induction Phase - Main criteria for exclusion include:

        Subjects who exhibit any of the following conditions are to be excluded from the study:

        (1) Severe UC defined by the following criteria: 6 bloody stools daily with one or more of
        the following:

          -  a. oral temperature &gt; 37.8 degrees C or &gt; 100.0 degrees F

          -  b. pulse &gt; 90 beats/min

          -  c. haemoglobin &lt; 10 g/dL (2) Treatment with oral mesalamine at a dose of &gt; 2.4 g/day
             within 4 weeks prior to randomisation.

             (3) Treatment with topical therapy (mesalamine or corticosteroids) within 2 weeks
             prior to randomisation (4) Treatment with systemic or rectal steroids within 4 weeks
             prior to randomisation.

             (5) Treatment with immunosuppressants within 6 weeks prior to randomisation. (6)
             Treatment with infliximab or other biologics within 3 months prior to randomisation.

             (7) Treatment with antibiotics within 7 days prior to randomisation. (8) Treatment
             with probiotics within 7 days prior to randomisation. (9) Treatment with
             anti-diarrhoeal treatment within 7 days prior to randomisation.

             (10) Treatment with nicotine patch within 7 days prior to randomisation. (11) Received
             any investigational drug within 30 days prior to randomisation. (12) History of
             colectomy or partial colectomy. (13) History of definite dysplasia in colonic
             biopsies. (14) Crohn's disease. (15) Immediate or significant risk of toxic megacolon.
             (16) Known bleeding disorders. (17) Hypersensitivity to salicylates, aspirin,
             sulfasalazine or mesalazine. (18) Serum creatinine &gt; 1.5 times the upper limit of the
             normal range. (19) Aspartate aminotransferase (AST), alanine aminotransferase (ALT),
             total bilirubin or alkaline phosphatase &gt; 2 times the upper limit of the normal range.

             (20) Serious underlying disease other than UC which in the opinion of the investigator
             may interfere with the subject's ability to fully participate in the study.

             (21) History of alcohol or drug abuse which in the opinion of the investigator may
             interfere with the subject's ability to comply with the study procedures.

             (22) Stools positive for Clostridium difficile toxin. (23) Pregnant or lactating
             women. (24) Prior enrolment in the study.

        OLE - Main criteria for inclusion include:

          1. Attendance at the Week 8 visit and completion of disease activity assessments prior to
             enrolment in OLE at Week 12 (responders or remitters) or Week 8 (non-responders).

          2. At least 75% compliance with study medication in the induction phase.

        OLE - Main criteria for exclusion include:

        (1) Withdrawal from the induction phase prior to the Week 8 visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geert R D'Haens, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Robarts Clinical Trials Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tillotts Pharma AG</name>
      <address>
        <city>Rheinfelden</city>
        <state>Baslerstrasse 15</state>
        <zip>4310</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <removed_countries>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>July 9, 2013</study_first_submitted>
  <study_first_submitted_qc>July 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2013</study_first_posted>
  <results_first_submitted>May 22, 2017</results_first_submitted>
  <results_first_submitted_qc>August 6, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 8, 2018</results_first_posted>
  <last_update_submitted>August 6, 2018</last_update_submitted>
  <last_update_submitted_qc>August 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>UC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesalamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>TP05 (Mesalazine) 1600 mg</title>
          <description>3.2g/day once daily (OD) for 12 weeks (blinded),</description>
        </group>
        <group group_id="P2">
          <title>Asacol (Mesalazine 400 mg)</title>
          <description>3.2g/d twice daily for 12 weeks (blinded),</description>
        </group>
        <group group_id="P3">
          <title>Extended Induction</title>
          <description>Non-responders at week 8 of the induction phase were taken out of the double-blind phase and treated with TP05 4.8g/day OD for another 8 weeks</description>
        </group>
        <group group_id="P4">
          <title>1.6g TP05 (1600 mg) /Day Maintenance Open-Label</title>
          <description>Remitters at week 12 of the induction phase received a daily dose of 1.6g OD in the maintenance phase open-label.</description>
        </group>
        <group group_id="P5">
          <title>3.2g TP05 (1600 mg) /Day Maintenance Open-Label</title>
          <description>Responders at week 12 of the induction phase remained on a daily dose of 3.2 g OD in the maintenance phase open-label.</description>
        </group>
        <group group_id="P6">
          <title>4.8g TP05 (1600 mg) /Day Maintenance Open-Label</title>
          <description>Non-responders at week 12 of the double-blind induction phase as well as non-responders at week 8 of the induction phase who responded after a second 8 weeks of extended induction treatments, were enrolled into the maintenance phase and remained on a daily dose of 4.8g OD.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double-Blind Induction</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="409"/>
                <participants group_id="P2" count="408"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="370"/>
                <participants group_id="P2" count="367"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>non-compliance,</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extended Induction, Open-Label</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0">This treatment arm was only used in Period 1, double-blind induction phase.</participants>
                <participants group_id="P3" count="243">The subjects in this phase were non-responders at week 8 and discontinued the double-blind phase.</participants>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="220"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Maintenance, Open-Label</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0">Period 2 (extended induction) is completed, subjects are newly allocated to Period 3, maintenance.</participants>
                <participants group_id="P4" count="202">This is period 3, Open-Label Maintenance following on from period 1, the double-blind induction.</participants>
                <participants group_id="P5" count="274">This is period 3, Open-Label Maintenance following on from period 1, the double-blind induction.</participants>
                <participants group_id="P6" count="199">This is period 3, Open-Label Maintenance following on from period 1, the double-blind induction.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="196"/>
                <participants group_id="P5" count="253"/>
                <participants group_id="P6" count="181"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="21"/>
                <participants group_id="P6" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Population (SAF)/Intent to Treat (ITT)</population>
      <group_list>
        <group group_id="B1">
          <title>TP05 (Mesalazine)</title>
          <description>3.2 gram/day (g/d) once daily (OD) for 12 weeks (blinded),</description>
        </group>
        <group group_id="B2">
          <title>Asacol (Mesalazine, Tillotts Pharma AG)</title>
          <description>3.2g/d twice daily for 12 weeks (blinded),</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="409"/>
            <count group_id="B2" value="408"/>
            <count group_id="B3" value="817"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.97" spread="14.54"/>
                    <measurement group_id="B2" value="43.3" spread="14.11"/>
                    <measurement group_id="B3" value="43.5" spread="14.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="171"/>
                    <measurement group_id="B2" value="178"/>
                    <measurement group_id="B3" value="349"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="238"/>
                    <measurement group_id="B2" value="230"/>
                    <measurement group_id="B3" value="468"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="378"/>
                    <measurement group_id="B2" value="386"/>
                    <measurement group_id="B3" value="764"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian or Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mixed/Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Available</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Belarus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bulgaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Finland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ireland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Latvia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lithuania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Norway</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serbia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovakia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mayo Score</title>
          <description>Mayo Score and Partial Mayo Clinic Score (PMCS):
The Mayo scoring system is a well-established tool for assessing UC disease activity. The Mayo score is the sum of 4 component sub-scores, each ranging from 0 representing no pathology to 3 for severe disease. The 4 component sub-scores are: 1) stool frequency, 2) rectal bleeding, 3) flexible sigmoidoscopy scores, and 4) physician’s global assessment. The minimum Mayo Score is 0 (no pathology) and the maximum is 12 (severe disease in all sub-scores).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.7" spread="1.3"/>
                    <measurement group_id="B2" value="7.6" spread="1.3"/>
                    <measurement group_id="B3" value="7.7" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Partial Mayo Clinic Score</title>
          <description>Partial Mayo Clinic Score (PMCS) is the sum of the component sub-scores, excluding the endoscopic score. The 3 component sub-scores are: 1) stool frequency, 2) rectal bleeding, and 3) physician's global assessment. The minimum is 0, no pathology and the maximum is 9, severe disease in all sub-scores.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.5" spread="1.1"/>
                    <measurement group_id="B2" value="5.3" spread="1.1"/>
                    <measurement group_id="B3" value="5.4" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Period 1: Clinical and Endoscopic Remission</title>
        <description>Mayo Score of &lt;= 2 points with no individual sub-score &gt; 1</description>
        <time_frame>Week 8</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>TP05 (Mesalazine)</title>
            <description>3.2g/day once daily for 12 weeks (blinded),</description>
          </group>
          <group group_id="O2">
            <title>Asacol (Mesalazine, Tillotts Pharma AG)</title>
            <description>3.2g/d twice daily for 12 weeks (blinded),</description>
          </group>
        </group_list>
        <measure>
          <title>Period 1: Clinical and Endoscopic Remission</title>
          <description>Mayo Score of &lt;= 2 points with no individual sub-score &gt; 1</description>
          <population>Per Protocol</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="388"/>
                <count group_id="O2" value="386"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>If the lower limit of the confidence interval was no less than -10% it would be concluded that the test product is non-inferior to the comparator.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority, pre-defined non-inferiority margin 10% A two-sided 95% confidence interval about the difference in proportions was constructed. If the lower limit of the confidence interval was no less than -10% it would be concluded that the test product is non-inferior to the comparator.</non_inferiority_desc>
            <p_value>0.005</p_value>
            <method>Non-inferiority</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.1</ci_lower_limit>
            <ci_upper_limit>3.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Period 2: Clinical Response, Open-Label Extended Induction</title>
        <description>A decrease in the PMCS of ≥ 2 points and ≥ 30% from baseline, with a decrease in the rectal bleeding sub-score of ≥ 1 point or absolute rectal bleeding sub-score of 1 or 0.</description>
        <time_frame>Week 16</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Extended Induction</title>
            <description>Non-responders to blinded treatment at week 8 of the induction phase (Period 1) were moved to open-label extended induction treatment of an additional 8 weeks (Period 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Period 2: Clinical Response, Open-Label Extended Induction</title>
          <description>A decrease in the PMCS of ≥ 2 points and ≥ 30% from baseline, with a decrease in the rectal bleeding sub-score of ≥ 1 point or absolute rectal bleeding sub-score of 1 or 0.</description>
          <population>Intent to Treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentag</param_type>
            <param_value>75.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>69.4</ci_lower_limit>
            <ci_upper_limit>80.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Period 3: Clinical Remission</title>
        <description>Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS)</description>
        <time_frame>Week 38</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>1.6g/Day Maintenance Open-Label</title>
            <description>Remitters at week 12 of the induction phase (Period 1) received a daily dose of 1.6g in the maintenance open-labe phase ((Period 3)</description>
          </group>
          <group group_id="O2">
            <title>3.2/Day Maintenance Open-Label</title>
            <description>Responders at week 12 of the induction phase (Period 1) remaining on a daily dose of 3.2g in the maintenance phase open-label (Period 3)</description>
          </group>
          <group group_id="O3">
            <title>4.8g/Day Maintenance Open-Label</title>
            <description>Original non-responders at week 8 of the induction phase (Period 1) who responded to treatment after a second 8 weeks of extended induction open-label (Period 2), were enrolled into the maintenance phase open-label (Period 3) and remained on a daily dose of 4.8g.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 3: Clinical Remission</title>
          <description>Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS)</description>
          <population>Intent to Treat</population>
          <units>percentage of participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.3"/>
                    <measurement group_id="O2" value="33.9"/>
                    <measurement group_id="O3" value="30.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 1: Endoscopic Remission</title>
        <description>Endoscopic remission was defined as a Mayo endoscopy subscore of 0</description>
        <time_frame>Week 8</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>TP05 (Mesalazine)</title>
            <description>3.2g/day once daily for 12 weeks (blinded),</description>
          </group>
          <group group_id="O2">
            <title>Asacol (Mesalazine, Tillotts Pharma AG)</title>
            <description>3.2g/d twice daily for 12 weeks (blinded),</description>
          </group>
        </group_list>
        <measure>
          <title>Period 1: Endoscopic Remission</title>
          <description>Endoscopic remission was defined as a Mayo endoscopy subscore of 0</description>
          <population>Per Protocol</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="388"/>
                <count group_id="O2" value="386"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>non-inferiority</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Non-inferiority</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-2.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.5</ci_lower_limit>
            <ci_upper_limit>2.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 1: Endoscopic Response</title>
        <description>Endoscopic response was define as a reduction in the Mayo endoscopic sub score of at least one.</description>
        <time_frame>Week 8</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>TP05 (Mesalazine)</title>
            <description>3.2g/day once daily for 12 weeks (blinded)</description>
          </group>
          <group group_id="O2">
            <title>Asacol (Mesalazine, Tillotts Pharma AG)</title>
            <description>3.2g/d twice daily for 12 weeks (blinded)</description>
          </group>
        </group_list>
        <measure>
          <title>Period 1: Endoscopic Response</title>
          <description>Endoscopic response was define as a reduction in the Mayo endoscopic sub score of at least one.</description>
          <population>Per Protocol</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="388"/>
                <count group_id="O2" value="386"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185"/>
                    <measurement group_id="O2" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority</non_inferiority_desc>
            <p_value>0.026</p_value>
            <method>Non-inferiority</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-3.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.1</ci_lower_limit>
            <ci_upper_limit>3.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 1: Clinical Remission</title>
        <description>Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS)</description>
        <time_frame>Week 8</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>TP05 (Mesalazine)</title>
            <description>3.2g/day once daily for 12 weeks (blinded)</description>
          </group>
          <group group_id="O2">
            <title>Asacol (Mesalazine, Tillotts Pharma AG)</title>
            <description>3.2g/d twice daily for 12 weeks (blinded)</description>
          </group>
        </group_list>
        <measure>
          <title>Period 1: Clinical Remission</title>
          <description>Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS)</description>
          <population>Per Protocol</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="388"/>
                <count group_id="O2" value="386"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority</non_inferiority_desc>
            <p_value>0.048</p_value>
            <method>Non-inferiority</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-4.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.9</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 1: Rectal Bleeding Sub-score of 0</title>
        <description>Rectal bleeding sub-score of 0 was defined as a sub score on the rectal bleeding component of the Mayo score</description>
        <time_frame>Week 8</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>TP05 (Mesalazine)</title>
            <description>3.2g/day once daily for 12 weeks (blinded)</description>
          </group>
          <group group_id="O2">
            <title>Asacol (Mesalazine, Tillotts Pharma AG)</title>
            <description>3.2g/d twice daily for 12 weeks (blinded)</description>
          </group>
        </group_list>
        <measure>
          <title>Period 1: Rectal Bleeding Sub-score of 0</title>
          <description>Rectal bleeding sub-score of 0 was defined as a sub score on the rectal bleeding component of the Mayo score</description>
          <population>Per Protocol</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="388"/>
                <count group_id="O2" value="386"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="212"/>
                    <measurement group_id="O2" value="226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-Inferiority</non_inferiority_desc>
            <p_value>0.042</p_value>
            <method>Non-inferiortiy</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-3.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.8</ci_lower_limit>
            <ci_upper_limit>3.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 1: Clinical and Endoscopic Response</title>
        <description>Clinical and Endoscopic Response was defined as a decrease in the Mayo score of ≥3 points from baseline and a reduction of ≥ 30% from baseline with either an accompanying decrease in the rectal bleeding sub-score of at least 1 point or an absolute rectal bleeding sub-score of 0 or 1 at the Week 8 visit. If a subject withdrew from the study prior to Week 8 or their response status was not evaluable due to incomplete and/or invalid data, the subject was considered a non-responder.</description>
        <time_frame>Week 8</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>TP05 (Mesalazine)</title>
            <description>3.2g/day once daily at week 8</description>
          </group>
          <group group_id="O2">
            <title>Asacol (Mesalazine)</title>
            <description>3.2g/d twice daily at week 8</description>
          </group>
        </group_list>
        <measure>
          <title>Period 1: Clinical and Endoscopic Response</title>
          <description>Clinical and Endoscopic Response was defined as a decrease in the Mayo score of ≥3 points from baseline and a reduction of ≥ 30% from baseline with either an accompanying decrease in the rectal bleeding sub-score of at least 1 point or an absolute rectal bleeding sub-score of 0 or 1 at the Week 8 visit. If a subject withdrew from the study prior to Week 8 or their response status was not evaluable due to incomplete and/or invalid data, the subject was considered a non-responder.</description>
          <population>Per Protocol</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="388"/>
                <count group_id="O2" value="386"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="221"/>
                    <measurement group_id="O2" value="236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-Inferiority</non_inferiority_desc>
            <p_value>0.048</p_value>
            <method>Non-inferiority</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-4.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.0</ci_lower_limit>
            <ci_upper_limit>2.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 1: Clinical Remission</title>
        <description>Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS)</description>
        <time_frame>Week 12</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>TP05 (Mesalazine)</title>
            <description>3.2g/day once daily for 12 weeks (blinded)</description>
          </group>
          <group group_id="O2">
            <title>Asacol (Mesalazine, Tillotts Pharma AG)</title>
            <description>3.2g/d twice daily for 12 weeks (blinded)</description>
          </group>
        </group_list>
        <measure>
          <title>Period 1: Clinical Remission</title>
          <description>Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS)</description>
          <population>Per Protocol</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="388"/>
                <count group_id="O2" value="386"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority</non_inferiority_desc>
            <p_value>0.068</p_value>
            <method>Non-inferiority</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-5.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.5</ci_lower_limit>
            <ci_upper_limit>0.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 1: Clinical Response</title>
        <description>A decrease in the PMCS of ≥ 2 points and ≥ 30% from baseline, with a decrease in the rectal bleeding sub-score of ≥ 1 point or absolute rectal bleeding sub-score of 1 or 0.</description>
        <time_frame>Week 12</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>TP05 (Mesalazine)</title>
            <description>3.2g/day once daily for 12 weeks (blinded)</description>
          </group>
          <group group_id="O2">
            <title>Asacol (Mesalazine, Tillotts Pharma AG)</title>
            <description>3.2g/d twice daily for 12 weeks (blinded)</description>
          </group>
        </group_list>
        <measure>
          <title>Period 1: Clinical Response</title>
          <description>A decrease in the PMCS of ≥ 2 points and ≥ 30% from baseline, with a decrease in the rectal bleeding sub-score of ≥ 1 point or absolute rectal bleeding sub-score of 1 or 0.</description>
          <population>Per protocol</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="388"/>
                <count group_id="O2" value="386"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223"/>
                    <measurement group_id="O2" value="233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority</non_inferiority_desc>
            <p_value>0.021</p_value>
            <method>Non-inferiortiy</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-2.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.8</ci_lower_limit>
            <ci_upper_limit>4.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 1: Rectal Bleeding Score of 0</title>
        <description>Rectal bleeding sub-score of 0 was defined as a sub score on the rectal bleeding component of the Mayo score</description>
        <time_frame>Week 12</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>TP05 (Mesalazine)</title>
            <description>3.2g/day once daily for 12 weeks (blinded)</description>
          </group>
          <group group_id="O2">
            <title>Asacol (Mesalazine, Tillotts Pharma AG)</title>
            <description>3.2g/d twice daily for 12 weeks (blinded)</description>
          </group>
        </group_list>
        <measure>
          <title>Period 1: Rectal Bleeding Score of 0</title>
          <description>Rectal bleeding sub-score of 0 was defined as a sub score on the rectal bleeding component of the Mayo score</description>
          <population>Per Protocol</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="388"/>
                <count group_id="O2" value="386"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="193"/>
                    <measurement group_id="O2" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority</non_inferiority_desc>
            <p_value>0.031</p_value>
            <method>Non-inferiortiy</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-3.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.3</ci_lower_limit>
            <ci_upper_limit>3.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 1: Clinical Remission at Both Week 8 and 12</title>
        <description>Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS)</description>
        <time_frame>Week 8 and week 12</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>TP05 (Mesalazine)</title>
            <description>3.2g/day once daily for 12 weeks (blinded)</description>
          </group>
          <group group_id="O2">
            <title>Asacol (Mesalazine, Tillotts Pharma AG)</title>
            <description>3.2g/d twice daily for 12 weeks (blinded)</description>
          </group>
        </group_list>
        <measure>
          <title>Period 1: Clinical Remission at Both Week 8 and 12</title>
          <description>Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS)</description>
          <population>Per Protocol</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="388"/>
                <count group_id="O2" value="386"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority</non_inferiority_desc>
            <p_value>0.013</p_value>
            <method>Non-inferiority</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-3.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.2</ci_lower_limit>
            <ci_upper_limit>1.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 1: Clinical Response at Both Week 8 and Week 12</title>
        <description>A decrease in the Partial Mayo Score of ≥ 2 points and ≥ 30% from baseline, with a decrease in the rectal bleeding sub-score of ≥ 1 point or absolute rectal bleeding sub-score of 1 or 0.</description>
        <time_frame>Week 8 and Week 12</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>TP05 (Mesalazine)</title>
            <description>3.2g/day once daily for 12 weeks (blinded)</description>
          </group>
          <group group_id="O2">
            <title>Asacol (Mesalazine, Tillotts Pharma AG)</title>
            <description>3.2g/d twice daily for 12 weeks (blinded)</description>
          </group>
        </group_list>
        <measure>
          <title>Period 1: Clinical Response at Both Week 8 and Week 12</title>
          <description>A decrease in the Partial Mayo Score of ≥ 2 points and ≥ 30% from baseline, with a decrease in the rectal bleeding sub-score of ≥ 1 point or absolute rectal bleeding sub-score of 1 or 0.</description>
          <population>Per Protocol</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="388"/>
                <count group_id="O2" value="386"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216"/>
                    <measurement group_id="O2" value="230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority</non_inferiority_desc>
            <p_value>0.042</p_value>
            <method>Non-inferiority</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-3.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.8</ci_lower_limit>
            <ci_upper_limit>3.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 1: Change in Mayo Score From Baseline</title>
        <description>Between-Group Difference of Mayo Score, Change from Baseline The changes from baseline to week 8 values in Mayo scores are compared between the two treatment groups.
The Mayo scoring system is a well-established tool for assessing UC disease activity. The Mayo score is the sum of 4 component sub-scores, each scored on a scale ranging from 0 representing no pathology to 3 for severe disease. The 4 component sub-scores consist of, 1) stool frequency, 2) rectal bleeding, 3) flexible sigmoidoscopy scores, and 4) physician's global assessment. A Mayo score of 0 indicates no pathology and a score of 12, severe disease. Change from Baseline is calculated Baseline-score minus week 8-score. A larger change in Mayo score from baseline when patients experienced acute disease, indicates improvement and treatment success.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>TP05 (Mesalazine)</title>
            <description>3.2g/day once daily at week 8</description>
          </group>
          <group group_id="O2">
            <title>Asacol (Mesalazine)</title>
            <description>3.2g/d twice daily at week 8</description>
          </group>
        </group_list>
        <measure>
          <title>Period 1: Change in Mayo Score From Baseline</title>
          <description>Between-Group Difference of Mayo Score, Change from Baseline The changes from baseline to week 8 values in Mayo scores are compared between the two treatment groups.
The Mayo scoring system is a well-established tool for assessing UC disease activity. The Mayo score is the sum of 4 component sub-scores, each scored on a scale ranging from 0 representing no pathology to 3 for severe disease. The 4 component sub-scores consist of, 1) stool frequency, 2) rectal bleeding, 3) flexible sigmoidoscopy scores, and 4) physician's global assessment. A Mayo score of 0 indicates no pathology and a score of 12, severe disease. Change from Baseline is calculated Baseline-score minus week 8-score. A larger change in Mayo score from baseline when patients experienced acute disease, indicates improvement and treatment success.</description>
          <population>Per Protocol</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="371"/>
                <count group_id="O2" value="375"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="2.7"/>
                    <measurement group_id="O2" value="3.2" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.557</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 1: Change in Partial Mayo Score From Baseline</title>
        <description>Between-Group Difference of Partial Mayo Score, Change from Baseline to Week 8 The Partial Mayo Score is the sum of the component sub-scores, 1) stool frequency, 2) rectal bleeding and 3) physician's global assessment. A partial Mayo Score of 0 indicates no disease and a maximum score of 9 indicates severe symptoms. Change from Baseline is calculated Baseline-score minus week 8-score. A larger change in Partial Mayo Score from Baseline where patients experienced acute disease, indicates improvement and treatment success.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>TP05 (Mesalazine)</title>
            <description>3.2g/day once daily at week 8</description>
          </group>
          <group group_id="O2">
            <title>Asacol (Mesalazine)</title>
            <description>3.2g/d twice daily at week 8</description>
          </group>
        </group_list>
        <measure>
          <title>Period 1: Change in Partial Mayo Score From Baseline</title>
          <description>Between-Group Difference of Partial Mayo Score, Change from Baseline to Week 8 The Partial Mayo Score is the sum of the component sub-scores, 1) stool frequency, 2) rectal bleeding and 3) physician's global assessment. A partial Mayo Score of 0 indicates no disease and a maximum score of 9 indicates severe symptoms. Change from Baseline is calculated Baseline-score minus week 8-score. A larger change in Partial Mayo Score from Baseline where patients experienced acute disease, indicates improvement and treatment success.</description>
          <population>Per Protocol</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="387"/>
                <count group_id="O2" value="383"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="2.2"/>
                    <measurement group_id="O2" value="2.5" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.987</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 1: Change in Stool Frequency Score</title>
        <description>Between-Group Difference of Stool Frequency Score, Change from Baseline The changes from baseline to week 8 values in stool frequency will be compared between the two treatment groups. Values for stool frequency range between 0 and 3. A value of 0 indicates normal stool frequency, a value of 3 indicates 5 or more stools than normal. Change from Baseline is calculated Baseline-score minus week 8-score. A large difference between week 8 values and baselines indicates treatment success.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>TP05 (Mesalazine)</title>
            <description>3.2g/day once daily at week 8</description>
          </group>
          <group group_id="O2">
            <title>Asacol (Mesalazine)</title>
            <description>3.2g/d twice daily at week 8</description>
          </group>
        </group_list>
        <measure>
          <title>Period 1: Change in Stool Frequency Score</title>
          <description>Between-Group Difference of Stool Frequency Score, Change from Baseline The changes from baseline to week 8 values in stool frequency will be compared between the two treatment groups. Values for stool frequency range between 0 and 3. A value of 0 indicates normal stool frequency, a value of 3 indicates 5 or more stools than normal. Change from Baseline is calculated Baseline-score minus week 8-score. A large difference between week 8 values and baselines indicates treatment success.</description>
          <population>Per Protocol</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="387"/>
                <count group_id="O2" value="383"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="1.1"/>
                    <measurement group_id="O2" value="0.9" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.455</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
            <estimate_desc>The result of the mean difference is not corresponding to the values in the table due to rounding as specified in the Statistical Analysis Plan (SAP).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 1: Change in Rectal Bleeding Score From Baseline</title>
        <description>Between-Group Difference of Rectal Bleeding Score, Change from Baseline The changes from baseline to week 8 values in rectal bleeding scores will be compared between the two treatment groups. A value of 0 indicates no rectal bleeding, a value of 3 indicates only blood is passing. Change from Baseline is calculated Baseline-score minus week 8-score. A large difference at week 8 compared to baseline is indicative of treatment success.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>TP05 (Mesalazine)</title>
            <description>3.2g/day once daily at week 8</description>
          </group>
          <group group_id="O2">
            <title>Asacol (Mesalazine)</title>
            <description>3.2g/d twice daily at week 8</description>
          </group>
        </group_list>
        <measure>
          <title>Period 1: Change in Rectal Bleeding Score From Baseline</title>
          <description>Between-Group Difference of Rectal Bleeding Score, Change from Baseline The changes from baseline to week 8 values in rectal bleeding scores will be compared between the two treatment groups. A value of 0 indicates no rectal bleeding, a value of 3 indicates only blood is passing. Change from Baseline is calculated Baseline-score minus week 8-score. A large difference at week 8 compared to baseline is indicative of treatment success.</description>
          <population>Per Protocol</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="387"/>
                <count group_id="O2" value="383"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.8"/>
                    <measurement group_id="O2" value="1.0" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.937</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
            <estimate_desc>The apparent difference between the values in the table and the mean difference is due to rounding as defined in the SAP.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 1: Change in Physician Global Assessment Score From Baseline</title>
        <description>Between-Group Difference of Physician Global Assessment Score, Change from Baseline.
The changes from baseline to week 8 values in the Physician Global Assessment score will be compared between the two treatment groups. A value of 0 means no pathology and a value of 3 means severe disease. Change from Baseline is calculated Baseline-score minus week 8-score. A large difference between baseline to week 8 indicates treatment success.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>TP05 (Mesalazine)</title>
            <description>3.2g/day once daily at week 8</description>
          </group>
          <group group_id="O2">
            <title>Asacol (Mesalazine)</title>
            <description>3.2g/d twice daily at week 8</description>
          </group>
        </group_list>
        <measure>
          <title>Period 1: Change in Physician Global Assessment Score From Baseline</title>
          <description>Between-Group Difference of Physician Global Assessment Score, Change from Baseline.
The changes from baseline to week 8 values in the Physician Global Assessment score will be compared between the two treatment groups. A value of 0 means no pathology and a value of 3 means severe disease. Change from Baseline is calculated Baseline-score minus week 8-score. A large difference between baseline to week 8 indicates treatment success.</description>
          <population>Per Protocol</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="387"/>
                <count group_id="O2" value="383"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.8"/>
                    <measurement group_id="O2" value="0.7" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.357</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 1: Change in Endoscopic Score From Baseline</title>
        <description>Between-Group Difference of Endoscopic Score, Change from Baseline. The changes from baseline to week 8 values in sigmoidoscopic (mucosal) appearance scores will be compared between the two treatment groups. A value of 0 in the endoscopic score means normal or inactive disease and a value of 3 means severe disease. Change from Baseline is calculated Baseline-score minus week 8-score. A large difference between baseline to week 8 indicates treatment success.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>TP05 (Mesalazine)</title>
            <description>3.2g/day once daily at week 8</description>
          </group>
          <group group_id="O2">
            <title>Asacol (Mesalazine)</title>
            <description>3.2g/d twice daily at week 8</description>
          </group>
        </group_list>
        <measure>
          <title>Period 1: Change in Endoscopic Score From Baseline</title>
          <description>Between-Group Difference of Endoscopic Score, Change from Baseline. The changes from baseline to week 8 values in sigmoidoscopic (mucosal) appearance scores will be compared between the two treatment groups. A value of 0 in the endoscopic score means normal or inactive disease and a value of 3 means severe disease. Change from Baseline is calculated Baseline-score minus week 8-score. A large difference between baseline to week 8 indicates treatment success.</description>
          <population>Per Protocol</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="371"/>
                <count group_id="O2" value="375"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.9"/>
                    <measurement group_id="O2" value="0.6" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.099</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>0.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 2: Clinical Remission</title>
        <description>Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS)</description>
        <time_frame>Week 16</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Extended Induction</title>
            <description>Non-responders to blinded treatment at week 8 of the induction phase (Period 1) were moved to open-label extended induction treatment of an additional 8 weeks (Period 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Period 2: Clinical Remission</title>
          <description>Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS)</description>
          <population>Intent to Treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Percentage</param_type>
            <param_value>21.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>16.8</ci_lower_limit>
            <ci_upper_limit>27.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 2: Rectal Bleeding Sub-score of 0</title>
        <description>Percentage of patients achieving the endpoint rectal bleeding sub-score of 0</description>
        <time_frame>Week 16</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Extended Induction</title>
            <description>Non-responders to blinded treatment at week 8 of the induction phase (Period 1) were moved to open-label extended induction treatment of an additional 8 weeks (Period 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Period 2: Rectal Bleeding Sub-score of 0</title>
          <description>Percentage of patients achieving the endpoint rectal bleeding sub-score of 0</description>
          <population>Intent to treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Percentage</param_type>
            <param_value>60.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>53.6</ci_lower_limit>
            <ci_upper_limit>66.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 2: Stool Frequency 0</title>
        <description>Percentage of patients achieving the endpoint stool frequency sub-score of 0</description>
        <time_frame>Week 16</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Extended Induction</title>
            <description>Non-responders to blinded treatment at week 8 of the induction phase (Period 1) were moved to open-label extended induction treatment of an additional 8 weeks (Period 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Period 2: Stool Frequency 0</title>
          <description>Percentage of patients achieving the endpoint stool frequency sub-score of 0</description>
          <population>Intent to Treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Percentage</param_type>
            <param_value>26.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>20.9</ci_lower_limit>
            <ci_upper_limit>32.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 2: Urgency</title>
        <description>Percentage of patients achieving an Urgency Score of 0. A score of 0 indicates no urgency reported in any of the three days prior to the visit at week 16. A score of 1 indicates urgency reported in any of the three days prior to the visits.</description>
        <time_frame>Week 16</time_frame>
        <population>Indent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Extended Induction</title>
            <description>Non-responders to blinded treatment at week 8 of the induction phase (Period 1) were moved to open-label extended induction treatment of an additional 8 weeks (Period 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Period 2: Urgency</title>
          <description>Percentage of patients achieving an Urgency Score of 0. A score of 0 indicates no urgency reported in any of the three days prior to the visit at week 16. A score of 1 indicates urgency reported in any of the three days prior to the visits.</description>
          <population>Indent to Treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Percentage</param_type>
            <param_value>44.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>38.5</ci_lower_limit>
            <ci_upper_limit>51.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 2: UC-Related Complications</title>
        <description>Percentage of Patients Experiencing Complications related to UC</description>
        <time_frame>Week 16</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Extended Induction</title>
            <description>Non-responders to blinded treatment at week 8 of the induction phase (Period 1) were moved to open-label extended induction treatment of an additional 8 weeks (Period 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Period 2: UC-Related Complications</title>
          <description>Percentage of Patients Experiencing Complications related to UC</description>
          <population>Intent to Treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Percentage</param_type>
            <param_value>0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 3: Clinical Response</title>
        <description>A decrease in the PMCS of ≥ 2 points and ≥ 30% from baseline, with a decrease in the rectal bleeding sub-score of ≥ 1 point or absolute rectal bleeding sub-score of 1 or 0.</description>
        <time_frame>Week 38</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>1.6g/Day Maintenance Open-Label</title>
            <description>Remitters at week 12 of the induction phase (Period 1) received a daily dose of 1.6g in the maintenance open-labe phase ((Period 3)</description>
          </group>
          <group group_id="O2">
            <title>3.2/Day Maintenance Open-Label</title>
            <description>Responders at week 12 of the induction phase (Period 1) remaining on a daily dose of 3.2g in the maintenance phase open-label (Period 3)</description>
          </group>
          <group group_id="O3">
            <title>4.8g/Day Maintenance Open-Label</title>
            <description>Original non-responders at week 8 of the induction phase (Period 1) who responded to treatment after a second 8 weeks of extended induction open-label (Period 2), were enrolled into the maintenance phase open-label (Period 3) and remained on a daily dose of 4.8g.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 3: Clinical Response</title>
          <description>A decrease in the PMCS of ≥ 2 points and ≥ 30% from baseline, with a decrease in the rectal bleeding sub-score of ≥ 1 point or absolute rectal bleeding sub-score of 1 or 0.</description>
          <population>Intent to Treat</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.1"/>
                    <measurement group_id="O2" value="83.9"/>
                    <measurement group_id="O3" value="78.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 3: Clinical and Endoscopic Remission</title>
        <description>Mayo Score of &lt;= 2 points with no individual sub-score &gt; 1</description>
        <time_frame>Week 38</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>1.6g/Day Maintenance Open-Label</title>
            <description>Remitters at week 12 of the induction phase (Period 1) received a daily dose of 1.6g in the maintenance open-labe phase ((Period 3)</description>
          </group>
          <group group_id="O2">
            <title>3.2/Day Maintenance Open-Label</title>
            <description>Responders at week 12 of the induction phase (Period 1) remaining on a daily dose of 3.2g in the maintenance phase open-label (Period 3)</description>
          </group>
          <group group_id="O3">
            <title>4.8g/Day Maintenance Open-Label</title>
            <description>Original non-responders at week 8 of the induction phase (Period 1) who responded to treatment after a second 8 weeks of extended induction open-label (Period 2), were enrolled into the maintenance phase open-label (Period 3) and remained on a daily dose of 4.8g.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 3: Clinical and Endoscopic Remission</title>
          <description>Mayo Score of &lt;= 2 points with no individual sub-score &gt; 1</description>
          <population>Intent to Treat</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.8"/>
                    <measurement group_id="O2" value="39.4"/>
                    <measurement group_id="O3" value="29.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 3: Clinical and Endoscopic Response</title>
        <description>Both has to be achieved, Clinical and Endoscopic Response which is defined by a decrease from baseline in the Mayo score of ≥ 3 points and &gt; 30% of the baseline score, with an accompanying decrease in the rectal bleeding sub-score of ≥ 1 point or an absolute rectal bleeding sub-score of 0 or 1.</description>
        <time_frame>Week 38</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>1.6g/Day Maintenance Open-Label</title>
            <description>Remitters at week 12 of the induction phase (Period 1) received a daily dose of 1.6g in the maintenance open-labe phase ((Period 3)</description>
          </group>
          <group group_id="O2">
            <title>3.2/Day Maintenance Open-Label</title>
            <description>Responders at week 12 of the induction phase (Period 1) remaining on a daily dose of 3.2g in the maintenance phase open-label (Period 3)</description>
          </group>
          <group group_id="O3">
            <title>4.8g/Day Maintenance Open-Label</title>
            <description>Original non-responders at week 8 of the induction phase (Period 1) who responded to treatment after a second 8 weeks of extended induction open-label (Period 2), were enrolled into the maintenance phase open-label (Period 3) and remained on a daily dose of 4.8g.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 3: Clinical and Endoscopic Response</title>
          <description>Both has to be achieved, Clinical and Endoscopic Response which is defined by a decrease from baseline in the Mayo score of ≥ 3 points and &gt; 30% of the baseline score, with an accompanying decrease in the rectal bleeding sub-score of ≥ 1 point or an absolute rectal bleeding sub-score of 0 or 1.</description>
          <population>Intent to Treat</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.6"/>
                    <measurement group_id="O2" value="78.1"/>
                    <measurement group_id="O3" value="69.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 3: Endoscopic Remission</title>
        <description>Percentage of each dose group achieving an endoscopy sub score of 0</description>
        <time_frame>Week 38</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>1.6g/Day Maintenance Open-Label</title>
            <description>Remitters at week 12 of the induction phase (Period 1) received a daily dose of 1.6g in the maintenance open-labe phase ((Period 3)</description>
          </group>
          <group group_id="O2">
            <title>3.2/Day Maintenance Open-Label</title>
            <description>Responders at week 12 of the induction phase (Period 1) remaining on a daily dose of 3.2g in the maintenance phase open-label (Period 3)</description>
          </group>
          <group group_id="O3">
            <title>4.8g/Day Maintenance Open-Label</title>
            <description>Original non-responders at week 8 of the induction phase (Period 1) who responded to treatment after a second 8 weeks of extended induction open-label (Period 2), were enrolled into the maintenance phase open-label (Period 3) and remained on a daily dose of 4.8g.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 3: Endoscopic Remission</title>
          <description>Percentage of each dose group achieving an endoscopy sub score of 0</description>
          <population>Intent to Treat</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.6"/>
                    <measurement group_id="O2" value="32.4"/>
                    <measurement group_id="O3" value="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 3: Endoscopic Response</title>
        <description>Endoscopic response was define as a reduction in the Mayo endoscopic sub score of at least one.</description>
        <time_frame>Week 38</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>1.6g/Day Maintenance Open-Label</title>
            <description>Remitters at week 12 of the induction phase (Period 1) received a daily dose of 1.6g in the maintenance open-labe phase ((Period 3)</description>
          </group>
          <group group_id="O2">
            <title>3.2/Day Maintenance Open-Label</title>
            <description>Responders at week 12 of the induction phase (Period 1) remaining on a daily dose of 3.2g in the maintenance phase open-label (Period 3)</description>
          </group>
          <group group_id="O3">
            <title>4.8g/Day Maintenance Open-Label</title>
            <description>Original non-responders at week 8 of the induction phase (Period 1) who responded to treatment after a second 8 weeks of extended induction open-label (Period 2), were enrolled into the maintenance phase open-label (Period 3) and remained on a daily dose of 4.8g.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 3: Endoscopic Response</title>
          <description>Endoscopic response was define as a reduction in the Mayo endoscopic sub score of at least one.</description>
          <population>Intent to Treat</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.8"/>
                    <measurement group_id="O2" value="58.8"/>
                    <measurement group_id="O3" value="53.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 3: Rectal Bleeding Sub Score of 0</title>
        <description>Percentage of each dose group achieving the endpoint rectal bleeding subscore 0</description>
        <time_frame>Week 38</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>1.6g/Day Maintenance Open-Label</title>
            <description>Remitters at week 12 of the induction phase (Period 1) received a daily dose of 1.6g in the maintenance open-labe phase ((Period 3)</description>
          </group>
          <group group_id="O2">
            <title>3.2/Day Maintenance Open-Label</title>
            <description>Responders at week 12 of the induction phase (Period 1) remaining on a daily dose of 3.2g in the maintenance phase open-label (Period 3)</description>
          </group>
          <group group_id="O3">
            <title>4.8g/Day Maintenance Open-Label</title>
            <description>Original non-responders at week 8 of the induction phase (Period 1) who responded to treatment after a second 8 weeks of extended induction open-label (Period 2), were enrolled into the maintenance phase open-label (Period 3) and remained on a daily dose of 4.8g.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 3: Rectal Bleeding Sub Score of 0</title>
          <description>Percentage of each dose group achieving the endpoint rectal bleeding subscore 0</description>
          <population>Intent to Treat</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.1"/>
                    <measurement group_id="O2" value="76.3"/>
                    <measurement group_id="O3" value="74.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 3: Stool Frequency Sub-score 0</title>
        <description>Patients achieving a Stool Frequency sub-score of 0</description>
        <time_frame>Week 38</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>1.6g/Day Maintenance Open-Label</title>
            <description>Remitters at week 12 of the induction phase (Period 1) received a daily dose of 1.6g in the maintenance open-labe phase ((Period 3)</description>
          </group>
          <group group_id="O2">
            <title>3.2/Day Maintenance Open-Label</title>
            <description>Responders at week 12 of the induction phase (Period 1) remaining on a daily dose of 3.2g in the maintenance phase open-label (Period 3)</description>
          </group>
          <group group_id="O3">
            <title>4.8g/Day Maintenance Open-Label</title>
            <description>Original non-responders at week 8 of the induction phase (Period 1) who responded to treatment after a second 8 weeks of extended induction open-label (Period 2), were enrolled into the maintenance phase open-label (Period 3) and remained on a daily dose of 4.8g.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 3: Stool Frequency Sub-score 0</title>
          <description>Patients achieving a Stool Frequency sub-score of 0</description>
          <population>Intent to Treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148"/>
                    <measurement group_id="O2" value="101"/>
                    <measurement group_id="O3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 3: No Urgency</title>
        <description>No urgency is a score of 0 and indicates that patients did not report urgency during any of the three days prior to the visit at week 38. A score of 1 indicates that urgency was reported during any of these three days.</description>
        <time_frame>Week 38</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>1.6g/Day Maintenance Open-Label</title>
            <description>Remitters at week 12 of the induction phase (Period 1) received a daily dose of 1.6g in the maintenance open-labe phase ((Period 3)</description>
          </group>
          <group group_id="O2">
            <title>3.2/Day Maintenance Open-Label</title>
            <description>Responders at week 12 of the induction phase (Period 1) remaining on a daily dose of 3.2g in the maintenance phase open-label (Period 3)</description>
          </group>
          <group group_id="O3">
            <title>4.8g/Day Maintenance Open-Label</title>
            <description>Original non-responders at week 8 of the induction phase (Period 1) who responded to treatment after a second 8 weeks of extended induction open-label (Period 2), were enrolled into the maintenance phase open-label (Period 3) and remained on a daily dose of 4.8g.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 3: No Urgency</title>
          <description>No urgency is a score of 0 and indicates that patients did not report urgency during any of the three days prior to the visit at week 38. A score of 1 indicates that urgency was reported during any of these three days.</description>
          <population>Intent to Treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161"/>
                    <measurement group_id="O2" value="173"/>
                    <measurement group_id="O3" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Period 3: UC-Related Complications</title>
        <description>Percentage of Patients with Complications related to UC</description>
        <time_frame>Week 38</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>1.6g/Day Maintenance Open-Label</title>
            <description>Remitters at week 12 of the induction phase (Period 1) received a daily dose of 1.6g in the maintenance open-labe phase (Period 3)</description>
          </group>
          <group group_id="O2">
            <title>3.2/Day Maintenance Open-Label</title>
            <description>Responders at week 12 of the induction phase (Period 1) remaining on a daily dose of 3.2g in the maintenance phase open-label (Period 3)</description>
          </group>
          <group group_id="O3">
            <title>4.8g/Day Maintenance Open-Label</title>
            <description>Original non-responders at week 8 of the induction phase (Period 1) who responded to treatment after a second 8 weeks of extended induction open-label (Period 2), were enrolled into the maintenance phase open-label (Period 3) and remained on a daily dose of 4.8g.</description>
          </group>
        </group_list>
        <measure>
          <title>Period 3: UC-Related Complications</title>
          <description>Percentage of Patients with Complications related to UC</description>
          <population>Intent to Treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years, 11 months</time_frame>
      <desc>Adverse Events (AEs) were analysed for each arm of the double-blind Induction Phase, for the Open-Label Extended Induction Phase and combined for the double-blind Induction Phase and the Open-Label Maintenance Phase but not for the Open-Label Maintenance Phase separately. In adding safety results of the Maintenance Phase to the safety results of the Induction Phase ensured that one occurence of an AE was counted as one AE and not as two when AEs continued from one phase to the other.</desc>
      <group_list>
        <group group_id="E1">
          <title>TP05/TP05</title>
          <description>Double-blind Induction Phase: TP05, and Open-Label Maintenance Phase: TP05</description>
        </group>
        <group group_id="E2">
          <title>Asacol/TP05</title>
          <description>Double-blind Induction Phase: Asacol, and Open-Label Maintenance Phase: TP05</description>
        </group>
        <group group_id="E3">
          <title>TP05 Extended Induction</title>
          <description>Extended Induction only, Open-Label</description>
        </group>
        <group group_id="E4">
          <title>TP05</title>
          <description>Double-blind Induction Phase only</description>
        </group>
        <group group_id="E5">
          <title>Asacol</title>
          <description>Double-blind Induction Phase only</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDra (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="243"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="409"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="408"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <description>Iron deficiency</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="409"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="408"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="408"/>
              </event>
              <event>
                <sub_title>Artrial fibrilation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="408"/>
              </event>
              <event>
                <sub_title>Unstable angina</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="408"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Deterioration ulcerative colities</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="409"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="409"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="408"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="408"/>
              </event>
              <event>
                <sub_title>Chronic pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="408"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Clostridium dificile</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="408"/>
              </event>
              <event>
                <sub_title>Chronic tonsilitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="408"/>
              </event>
              <event>
                <sub_title>Flue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="408"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="408"/>
              </event>
              <event>
                <sub_title>Perichondritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="408"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="408"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="408"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes melitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="408"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Herniated disc</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="408"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="408"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="408"/>
              </event>
              <event>
                <sub_title>Cerebral haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="408"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Fading fetus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="408"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="408"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute heamorrhagic cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="408"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal septum deformation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="408"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="408"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Cryoglobulinemic vasculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="409"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="409"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="408"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDra 18</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="409"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="409"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="408"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening of UC</sub_title>
                <description>Symptoms of active ulcerative colitis</description>
                <counts group_id="E1" events="59" subjects_affected="58" subjects_at_risk="409"/>
                <counts group_id="E2" events="75" subjects_affected="75" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E4" events="27" subjects_affected="26" subjects_at_risk="409"/>
                <counts group_id="E5" events="22" subjects_affected="22" subjects_at_risk="408"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Robert Hofmann, MD PhD</name_or_title>
      <organization>Tillotts Pharma AG</organization>
      <phone>+4161 935 27 14</phone>
      <email>robert.hofmann@tillotts.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

